78 completed, 18 unknown, 14 recruiting, 9 withdrawn. 138 Phase 3, 14 Phase 2.
Follow Purpura: new trials by email Literature Review of Purpura trials Research Report on Purpura
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP) Romiplostim, Predniso(lo)ne - Primary Immune Thrombocytopenia | Phase 3 | Recruiting | Amgen | 126 | 2026-08-21 | 2026-09-17 |
| Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia Sirolimus, Placebo - Systemic Lupus Erythematosus, Immune Thrombocytopenia | Phase 2 / Phase 3 | Recruiting | Chinese SLE Treatment And Research Group | 164 | 2026-06-07 | 2026-06-18 |
| ATRA for Management of Primary ITP all-trans retinoic acid (ATRA), Placebo - Immune Thrombocytopenia | Phase 3 | Not yet recruiting | Peking University People's Hospital | 192 | 2026-05-30 | 2026-05-19 |
| Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients QL0911, Placebo - Thrombocytopenia, Immune | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 60 | 2026-04-20 | 2026-03-06 |
| High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia High-Dose Dexamethasone Combined with Orelabrutinib, High-Dose Dexamethasone Combined with Placebo - Primary Immune Thrombocytopenia (ITP) | Phase 3 | Recruiting | Shandong University | 86 | 2026-04-08 | 2026-04-30 |
| Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia Avatrombopag+All trans retinoic acid, Avatrombopag - ITP - Immune Thrombocytopenia | Phase 2 / Phase 3 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 248 | 2025-12-01 | 2025-12-12 |
| An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia Human immunoglobulin (pH4) for intravenous injection - Primary Immune Thrombocytopenia (ITP) | Phase 3 | Recruiting | Grand Shuyang Life Sciences (Chengdu) Co., Ltd. | 36 | 2025-11-24 | 2026-04-08 |
| Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment rilzabrutinib - Immune Thrombocytopenia | Phase 3 | Recruiting | Sanofi | 60 | 2025-10-24 | 2026-11-12 |
| A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP) Efgartigimod IV, Placebo IV - Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia | Phase 2 / Phase 3 | Recruiting | argenx | 24 | 2025-10-20 | 2026-10-16 |
| Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan rilzabrutinib - Immune Thrombocytopenia | Phase 3 | Active not recruiting | Sanofi | 3 | 2025-10-15 | 2026-11-10 |
| The Holistic Study Avatrombopag, Rituximab (Arm B) - Thrombocytopenia Purpura | Phase 3 | Not yet recruiting | Ostfold Hospital Trust | 220 | 2025-09-15 | 2025-09-09 |
| A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia Mezagitamab - Immune Thrombocytopenic Purpura (ITP) | Phase 3 | Recruiting | Takeda | 150 | 2025-08-14 | 2026-10-30 |
| A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP) Kedrion IVIG 10% - Chronic Primary Immune Thrombocytopenia (ITP) | Phase 3 | Recruiting | Kedrion S.p.A. | 40 | 2025-08-13 | 2026-10-22 |
| V-IMMUNE® for Immune Thrombocytopenia 5% (5g/100 ml) intravenous immunoglobin - Immune Thrombocytopenia (ITP) | Phase 3 | Recruiting | On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA. | 31 | 2025-07-18 | 2026-01-20 |
| Study of Ravulizumab in Pediatric Participants With Primary IgAN Ravulizumab - IgAN, IgAVN | Phase 3 | Recruiting | Alexion Pharmaceuticals, Inc. | 36 | 2025-06-14 | 2026-07-30 |
| A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia TQB3473 Tablets, TQB3473 Placebo - Primary Immune Thrombocytopenia | Phase 3 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 199 | 2025-04-30 | 2025-05-20 |
| A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia Mezagitamab, Placebo - Immune Thrombocytopenic Purpura (ITP) | Phase 3 | Recruiting | Takeda | 171 | 2025-02-27 | 2026-11-04 |
| A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia Efgartigimod IV, Placebo IV - Primary Immune Thrombocytopenia (ITP) | Phase 3 | Recruiting | argenx | 69 | 2024-10-18 | 2026-05-01 |
| Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) Ianalumab, Placebo, Corticosteroids - Primary Immune Thrombocytopenia (ITP) | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 226 | 2023-02-03 | 2026-11-12 |
| A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids Ianalumab, Eltrombopag, Placebo - Primary Immune Thrombocytopenia | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 152 | 2023-02-02 | 2026-11-09 |
Showing 20 of 138. Sign in to see all of them.
Purpura, Thrombocytopenic, Idiopathic (120) · Thrombocytopenia (24) · Purpura, Thrombocytopenic (12) · Purpura, Thrombotic Thrombocytopenic (12) · Hemorrhage (8) · Hematologic Diseases (5) · Hemostatic Disorders (4) · Autoimmune Diseases (3) · Blood Platelet Disorders (3) · Hemorrhagic Disorders (3) · IgA Vasculitis (3) · Immune System Diseases (3) · Jacobs syndrome (3) · Cytopenia (2)
Hemic and Lymphatic Diseases (138) · Pathologic Processes (138) · Pathological Conditions, Signs and Symptoms (138) · Signs and Symptoms (138) · Blood Coagulation Disorders (137) · Skin Manifestations (136) · Thrombotic Microangiopathies (134) · Hematologic Diseases (133) · Cytopenia (132) · Blood Platelet Disorders (131) · Hemorrhage (130) · Immune System Diseases (122) · Purpura, Thrombocytopenic (122) · Hemorrhagic Disorders (121)
Dexamethasone (17) · Rituximab (17) · romiplostim (15) · Immunoglobulins, Intravenous (13) · eltrombopag (13) · Prednisone (7) · Thrombopoietin (7) · avatrombopag (7) · Prednisolone (5) · Standard of Care (5) · caplacizumab (4) · fostamatinib (4) · Adrenal Cortex Hormones (3) · Inosine Triphosphate (3) · Plasma Exchange (3)
Shandong University (16) · Amgen (10) · argenx (7) · Assistance Publique - Hôpitaux de Paris (5) · Novartis Pharmaceuticals (5) · Sanofi (5) · GlaxoSmithKline (4) · Jiangsu HengRui Medicine Co., Ltd. (3) · Octapharma (3) · Ostfold Hospital Trust (3) · Peking University People's Hospital (3) · Rigel Pharmaceuticals (3) · Sobi, Inc. (3) · Takeda (3) · UCB Biopharma SRL (3)
China (44) · United States (42) · Italy (30) · Spain (30) · United Kingdom (30) · France (28) · Poland (25) · Germany (24) · Japan (23) · Czechia (18) · Russia (18) · Austria (16) · Canada (16) · Hungary (16) · Australia (15)
Ming Hou, Dr (5) · Ming Hou, Dr. (4) · Charlotte Bradbury (2) · Cindy Leissinger, MD (2) · David Kuter, MD (2) · Ellis Neufeld, MD (2) · James Bussel, MD (2) · James George, MD (2)
PMID 19005182, PMID 19671919, PMID 33995988, PMID 12944568, PMID 17077333, PMID 18242413, PMID 19846889, PMID 21533818, PMID 22117897, PMID 22494019, PMID 12401245, PMID 18510702, PMID 19635187, PMID 19731307, PMID 20130241, PMID 20841509, PMID 20863431, PMID 22409309, PMID 23169778, PMID 23293082, PMID 23492914, PMID 23753021, PMID 23896965, PMID 24892422, PMID 25247485, PMID 25566808, PMID 25575541, PMID 25662413, PMID 26231455, PMID 26480931, PMID 27103127, PMID 28605168, PMID 28630121, PMID 28640947, PMID 28734636, PMID 29042367, PMID 29296854, PMID 29536526, PMID 29736158, PMID 30191972, PMID 30341143, PMID 30499734, PMID 30625070, PMID 30685874, PMID 30687970, PMID 31691462, PMID 32282882, PMID 32853584, PMID 32871029, PMID 33251910
2019 (5), 2017 (3), 2009 (2), 2023 (2), 2025 (2), U01HL072268 (2), 2004 (1), 2015 (1), 2016 (1), 2018 (1)